Ipsen Pharma
Records under this name other than patents Ipsen Pharma holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,827,637 | Azaindole Derivatives and Their Use as Erk Kinase Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 12,421,231 | Azaindole Derivatives and Their Use as Erk Kinase Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 10,792,433 | Syringe assembly Lapsed on the fee record Ended Oct 6, 2024 · From the USPTO record | Lapsed on the fee record | Ended Oct 6, 2024 | From the USPTO record |
| US 8,029,458 | Device for the injection of a solid or semi-solid implant Formerly held Lapsed on the fee record Ended Oct 4, 2023 · From the USPTO record | Lapsed on the fee record | Ended Oct 4, 2023 | From the USPTO record |
| US 9,080,220 | Simultaneous, separate or sequential therapeutic use of at least one botulinum neurotoxin and of at least one opiate derivative Formerly held Lapsed on the fee record Ended Jul 14, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jul 14, 2023 | From the USPTO record |
| US 7,897,578 | Peptides with anti-proliferative activity Formerly held Lapsed on the fee record Ended Mar 1, 2019 · From the USPTO record | Lapsed on the fee record | Ended Mar 1, 2019 | From the USPTO record |
| US 7,816,539 | Derivatives of benzimidazole and imidazo-pyridine and their use as medicaments Formerly held Lapsed on the fee record Ended Oct 19, 2018 · From the USPTO record | Lapsed on the fee record | Ended Oct 19, 2018 | From the USPTO record |
| US 7,763,725 | Pyrimido-benzimidazole derivatives and the use thereof in the form of agonists and antagonists of melanocortin receptors Formerly held Lapsed on the fee record Ended Jul 27, 2018 · From the USPTO record | Lapsed on the fee record | Ended Jul 27, 2018 | From the USPTO record |
| US 8,348,881 | Device for injecting a pharmaceutical active principle Formerly held Lapsed on the fee record Ended Jan 8, 2017 · From the USPTO record | Lapsed on the fee record | Ended Jan 8, 2017 | From the USPTO record |
| US 7,977,455 | Analogues of GLP-1 Formerly held Lapsed on the fee record Ended Jul 12, 2015 · From the USPTO record | Lapsed on the fee record | Ended Jul 12, 2015 | From the USPTO record |